The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$39.39

Today's change-0.75 -1.87%
Updated August 29 4:00 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$39.39

Today's change-0.75 -1.87%
Updated August 29 4:00 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc down $0.75

Valeant Pharmaceuticals International Inc closed sharply lower Monday, dropping $0.75 or 1.87% to $39.39. Over the last five days, shares have lost 2.86% and are down 71.98% for the last year to date. This security has underperformed the S&P TSX by 93.27% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward5.14×
  • Forward PEG0.31×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$3.69
Updated August 29 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-9.57%

Although this company's net profit margin is negative, it is above the industry average and implies that Valeant Pharmaceuticals International Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.29%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue2,4202,3722,7362,787
Total other revenue--------
Total revenue2,4202,3722,7362,787
Gross profit1,7621,7422,0602,139
Total cost of revenue658630677648
Total operating expense2,3402,3052,5422,339
Selling / general / administrative672813743698
Research & development12410396102
Depreciation / amortization888695789679
Interest expense (income), net operating--------
Unusual expense (income)4442195182
Other operating expenses, total-45234330
Operating income8166195448
Interest income (expense), net non-operating-473-427-433-420
Gain (loss) on sale of assets--------
Other--------
Income before tax-377-366-240-6
Income after tax-304-373-36252
Income tax, total-737122-57
Net income-302-374-36250
Total adjustments to net income--------
Net income before extra. items-302-374-36250
Minority interest2-11-2
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-302-374-36250
Inc. avail. to common incl. extra. items-302-374-36250
Diluted net income-302-374-36250
Dilution adjustment0------
Diluted weighted average shares345345348351
Diluted EPS excluding extraordinary itemsvalue per share-0.88-1.08-1.040.14
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.78-1.00-0.540.57